Jasper Therapeutics Inc Stock Price, News & Analysis

Jasper Therapeutics (NASDAQ:JSPR) reported Q2 2025 financial results and provided updates on briquilimab, its novel antibody therapy targeting c-Kit. The company reported strong efficacy data in chronic urticaria trials, with 89% complete response rate in CSU patients across 240mg and 360mg single-dose cohorts, and 92% complete response in CIndU patients in the 180mg SPOTLIGHT cohort.

However, the company is investigating anomalous results in two BEACON study cohorts where 11 of 13 patients showed no UAS7 reduction, potentially due to product lot variability. Jasper implemented a 50% workforce reduction to focus on urticaria programs and reported Q2 financials with $39.5M cash position and a net loss of $26.7M. The planned Phase 2b CSU study is now delayed to mid-2026.

Jasper Therapeutics (Nasdaq: JSPR) announced a significant corporate reorganization to extend its cash runway. The company is implementing a 50% workforce reduction and will focus exclusively on developing briquilimab for chronic urticaria programs. As part of the restructuring, Dr. Edwin Tucker will step down as Chief Medical Officer, with Dr. Daniel Adelman taking over as Acting CMO effective August 1, 2025.

The company is halting all other clinical and preclinical programs, including the ETESIAN study in asthma, SCID study, and ongoing investigator-sponsored studies. Jasper will concentrate resources on completing the BEACON, SPOTLIGHT and open label extension studies for briquilimab in chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), where the treatment has shown promising results with rapid, deep, and durable responses.

Jasper Therapeutics (NASDAQ:JSPR) reported mixed clinical data from its briquilimab studies in Chronic Spontaneous Urticaria (CSU). In the single-dose cohorts (240mg and 360mg), 8 of 9 participants (89%) achieved complete response, with 78% showing clinical response by week 2. The open-label extension study using 180mg Q8W showed 73% complete response rate at 12 weeks.

However, results from the 240mg Q8W and 240mg followed by 180mg Q8W cohorts were confounded by issues with one drug product lot. The company is investigating the affected lot and will enroll 10-12 additional patients across these cohorts. Due to the same lot issue, Jasper is halting the ETESIAN asthma study and SCID development, implementing cost-cutting measures. The Phase 2b CSU study is now delayed until mid-2026.

Jasper Therapeutics (NASDAQ: JSPR) reported positive data from the 180mg cohort of its SPOTLIGHT Phase 1b/2a study evaluating briquilimab in chronic inducible urticaria (CIndU). The study showed remarkable efficacy with 92% (11/12) of participants achieving complete response and 100% (12/12) achieving clinical response. The drug demonstrated rapid action with 66% of participants responding by week 2, and 58% maintaining response through week 8. Notably, 83% of participants showed tryptase levels below quantification limits. The treatment was well-tolerated with no serious adverse events or grade 3+ events reported. The study included 27 participants across three dose cohorts (40mg, 120mg, and 180mg), focusing on patients with cold urticaria or symptomatic dermographism who were refractory to antihistamines. The positive results suggest briquilimab's potential as a novel antibody therapy targeting KIT (CD117) for mast cell-driven diseases.

Jasper Therapeutics (NASDAQ: JSPR) announced the acceptance of four abstracts for presentation at the EAACI Congress 2025 in Glasgow, focusing on their novel antibody therapy briquilimab. The presentations will showcase initial clinical data from the SPOTLIGHT Phase 1b/2a study testing briquilimab in cold urticaria and symptomatic dermographism patients. The abstracts cover various aspects including results from the SPOTLIGHT study, protection against allergen-induced dermatitis in mice, disease control in chronic spontaneous urticaria patients, and effects on COPD-like features in asthma models. The presentations will take place on June 14-15, 2025, featuring both oral and poster sessions.

Jasper Therapeutics (NASDAQ: JSPR), a clinical-stage biotech company developing briquilimab, will present at two major healthcare investor conferences. The company will participate in the RBC Capital Markets 2025 Global Healthcare Conference on May 21, 2025, at 11:00 a.m. EDT in a fireside chat format, and the Jefferies 2025 Global Healthcare Conference on June 5, 2025, at 11:40 a.m. EDT as a presentation.

Briquilimab is a novel antibody therapy targeting KIT for mast cell-driven diseases including chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and asthma. Live webcasts will be available on Jasper's Investor Relations website, with replays accessible for 30 days after each presentation.

Jasper Therapeutics (NASDAQ: JSPR) reported Q1 2025 financial results and provided updates on its clinical programs. The company is advancing briquilimab, a novel antibody therapy targeting KIT for mast cell diseases. Key developments include:

The BEACON Phase 1b/2a study in chronic spontaneous urticaria (CSU) continues enrollment, with additional data expected in Q3 2025. The SPOTLIGHT Phase 1b/2a study completed enrollment for its final cohort in chronic inducible urticaria, with data expected at EAACI Congress in June 2025. The ETESIAN study in allergic asthma continues enrollment with initial data expected in H2 2025.

Financial highlights for Q1 2025:
- Cash position: $48.8 million
- R&D expenses: $16.2 million
- G&A expenses: $5.6 million
- Net loss: $21.2 million ($1.41 per share)

Jasper Therapeutics (Nasdaq: JSPR) presented updated clinical data from its Phase 1b/2a BEACON study and four preclinical studies for briquilimab at the AAAAI 2025 Annual Meeting. The latest data, with a cut-off date of January 31, 2025, includes one month of additional dosing and follow-up from 49 participants.

The study shows that briquilimab continues to demonstrate favorable safety profile in treating chronic spontaneous urticaria (CSU), with no additional adverse events related to c-Kit blockade. The treatment resulted in rapid and deep clinical responses in omalizumab-experienced patients with moderate to severe CSU.

Based on these positive results, Jasper plans to advance briquilimab into a Phase 2b operationally adaptive study in the second half of 2025. The company expects to report additional clinical data from approximately 70 patients treated with briquilimab doses of 180mg or higher by mid-year 2025, which will inform the final dose selection for the Phase 2b study.

Jasper Therapeutics (Nasdaq: JSPR) has announced a late-breaking oral presentation of briquilimab data from their Phase 1b/2a BEACON study in chronic spontaneous urticaria (CSU) at the upcoming 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando.

The presentation, scheduled for March 8, 2025, at 1 p.m. PST, will showcase data previously disclosed on January 8th, 2025, demonstrating briquilimab's impact on CSU patients. The abstract titled 'Briquilimab demonstrates rapid, clinically meaningful reduction in disease activity in adults with chronic spontaneous urticaria (CSU): Results from a Phase 1b/2a study' will be featured in the Late Breaking Research: Session 2.

Briquilimab is a novel antibody therapy targeting c-Kit, developed to address mast cell driven diseases including CSU, chronic inducible urticaria (CIndU), and asthma.